Search

Your search keyword '"Lee, Samuel"' showing total 119 results

Search Constraints

Start Over You searched for: Author "Lee, Samuel" Remove constraint Author: "Lee, Samuel" Database Journals@OVID Remove constraint Database: Journals@OVID
119 results on '"Lee, Samuel"'

Search Results

4. Joint Modeling of Clinical and Biomarker Data in Acute Kidney Injury Defines Unique Subphenotypes with Differing Outcomes

5. Joint Modeling of Clinical and Biomarker Data in Acute Kidney Injury Defines Unique Subphenotypes with Differing Outcomes

12. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting

13. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting

21. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

22. Medical research and audit skills training for undergraduates: an international analysis and student-focused needs assessment

26. EuroSurg: a new European student-driven research network in surgery

28. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

29. Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

30. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites

38. Ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin: FP03–02

41. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anaemia management in previously untreated patients with chronic hepatitis c receiving boceprevir plus peginterferon/ribavirin

43. Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: Command GT2/3 Study: 762

44. Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naïve HCV Patients: Interim Results of a Prospective, Randomized Trial: 759

Catalog

Books, media, physical & digital resources